Network pharmacologic approach also indicated that the “anti-sclerotic” effect of KBG involved vascular endothelial growth factor (VEGF) signaling pathway, which relates to the process of scleroderma microvasculature, and the Toll-like receptor signaling pathway, which is a pro-fibrotic process of scleroderma (29). This evidence concerns the gene VEGFA and scleroderma.